Cargando…
Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes
AIMS: Identification of patients with type 2 diabetes (T2D) at increased risk of incident heart failure (HF) beyond traditional risk factors such as prior myocardial infarction (MI) might allow selection of patients who would benefit from preventative treatment. Microvascular disease (MiVD) is thoug...
Autores principales: | Mordi, Ify R., Tee, Aaron, Palmer, Colin N., McCrimmon, Rory J., Doney, Alexander S.F., Lang, Chim C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261547/ https://www.ncbi.nlm.nih.gov/pubmed/32239805 http://dx.doi.org/10.1002/ehf2.12669 |
Ejemplares similares
-
Inflammation as a therapeutic target in heart failure with preserved ejection fraction
por: Peh, Zhen Hui, et al.
Publicado: (2023) -
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial
por: Mordi, Natalie A., et al.
Publicado: (2020) -
Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction
por: Curran, Fraser M., et al.
Publicado: (2021) -
Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
por: Mordi, Natalie A, et al.
Publicado: (2017) -
Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction
por: Zeng, Heng, et al.
Publicado: (2019)